9966 Panoramica delle azioni Alphamab Oncology, azienda biofarmaceutica in fase clinica, si occupa di ricerca e sviluppo, produzione e commercializzazione di farmaci biologici oncologici. Maggiori dettagli
Premi Analisi del rischio Non sono stati rilevati rischi per 9966 dai nostri controlli di rischio.
Vedi tutti gli assegni di rischio Catturate i vostri pensieri, i link e la narrativa aziendale
Alphamab Oncology Concorrenti Storia dei prezzi e prestazioni
Riepilogo dei massimi, dei minimi e delle variazioni dei prezzi delle azioni per Alphamab Oncology Prezzi storici delle azioni Prezzo attuale dell'azione HK$3.27 Massimo di 52 settimane HK$6.33 Minimo di 52 settimane HK$2.00 Beta 0.37 Variazione di 1 mese -12.57% Variazione a 3 mesi -21.77% Variazione di 1 anno -46.31% Variazione a 3 anni -75.08% Variazione a 5 anni n/a Variazione dall'IPO -80.40%
Notizie e aggiornamenti recenti
Alphamab Oncology Announces Phase I/II Clinical Trial of JSKN033 Approval from Center for Drug Evaluation of National Medical Products Administration Dec 26
Alphamab Oncology Presents the Phase II Clinical Data of KN046 in Combination with Axitinib for the Treatment of Advanced NSCLC at ESMO IO Congress 2024 Dec 13
Alphamab Oncology Announces Clinical Trial (Study Id: JSKN033-102) of JSKN033 Nov 13
Alphamab Oncology Presents the Latest Clinical Data of Anti-Her2 Bispecific ADC Subcutaneous Co-Formulation JSKN033 at SITC 2024 Nov 11
Alphamab Oncology Announces Board and Board Committee Changes Oct 22
New major risk - Share price stability Sep 30 Vedi altri aggiornamenti
Alphamab Oncology Announces Phase I/II Clinical Trial of JSKN033 Approval from Center for Drug Evaluation of National Medical Products Administration Dec 26
Alphamab Oncology Presents the Phase II Clinical Data of KN046 in Combination with Axitinib for the Treatment of Advanced NSCLC at ESMO IO Congress 2024 Dec 13
Alphamab Oncology Announces Clinical Trial (Study Id: JSKN033-102) of JSKN033 Nov 13
Alphamab Oncology Presents the Latest Clinical Data of Anti-Her2 Bispecific ADC Subcutaneous Co-Formulation JSKN033 at SITC 2024 Nov 11
Alphamab Oncology Announces Board and Board Committee Changes Oct 22
New major risk - Share price stability Sep 30
First half 2024 earnings released: CN¥0.047 loss per share (vs CN¥0.042 loss in 1H 2023) Sep 26
Alphamab Oncology Presented the Latest Clinical Data from Two Studies on Anti-Her2 Bispecific Adc Jskn003 At the Esmo Congress 2024 Sep 16
Alphamab Oncology Announces Updates in Relation to A Phase III Clinical Trial of KN046 for the Treatment of Advanced SQ NSCLC Sep 10
Insufficient new directors Sep 01
Alphamab Oncology (SEHK:9966) commences an Equity Buyback Plan for 96,492,380 shares, representing 10% of its issued share capital, under the authorization approved on June 12, 2024. Aug 29 Alphamab Oncology (SEHK:9966) commences an Equity Buyback Plan for 96,492,380 shares, representing 10% of its issued share capital, under the authorization approved on June 12, 2024. Aug 28
First half 2024 earnings released: CN¥0.047 loss per share (vs CN¥0.042 loss in 1H 2023) Aug 20
Alphamab Oncology to Report First Half, 2024 Results on Aug 15, 2024 Aug 02
Alphamab Oncology Presents Chinese Clinical Data of Anti-HER2 Bispecific ADC JSKN003 for the First Time at the 2024 ASCO Annual Meeting Jun 05
Alphamab Oncology Provides Updates in Relation to A Phase III Clinical Trial of KN046 for the Treatment of Advanced PDAC May 29
New major risk - Share price stability May 29
Alphamab Oncology Announces First Patient Has Been Successfully Dosed in A Phase I Clinical Trial of JSKN016 May 23
Alphamab Oncology Announces Updates on Results of a Phase I Clinical Trial of JSKN003 for the Treatment of HER2-Expressing Advanced Solid Tumors for Presentation at 2024 AACR Annual Meeting Apr 11
Alphamab Oncology Presented the Dose-Escalation Results from Jskn003 in Patients with Advanced/Metastatic Solid Tumors At Aacr Apr 10
New minor risk - Share price stability Apr 08
Full year 2023 earnings released: CN¥0.22 loss per share (vs CN¥0.35 loss in FY 2022) Mar 30
No longer forecast to breakeven Mar 30
Alphamab Oncology, Annual General Meeting, Jun 12, 2024 Mar 29
Alphamab Oncology Announces the First Patient Dosed in Australia in the Clinical Study of Subcutaneous Formulation JSKN033 Mar 27
Alphamab Oncology Announces Results of Phase II Clinical Study of Kn046 Plus Chemotherapy as First-Line Treatment for Metastatic Nsclc Were Published in Cell Reports Medicine Mar 22
Alphamab Oncology to Report Fiscal Year 2023 Results on Mar 28, 2024 Mar 19
Alphamab Oncology Announces Results of Phase II Clinical Study of KN046 in Combination with Nab-paclitaxel in TNBC were Published in Nature Communications Feb 07
Alphamab Oncology Announces Phase I/II Clinical Trial of Jskn033 Independently Developed by Group for the Treatment of Human Epidermal Growth Factor Receptor Dec 08
Alphamab Oncology Announces First Patient Dosed in Phase Iii Study of Jskn003 for the Treatment of Advanced Her2-Low Breast Cancer Dec 04
Alphamab Oncology Announces Preliminary Results of a Phase I Clinical Trial of JSKN003 in Australia for the Treatment of Her2-Expressing Advanced Solid Tumors Nov 17
New major risk - Revenue and earnings growth Nov 16
New minor risk - Share price stability Nov 14
Alphamab Oncology and CSPC Pharmaceutical Group Co., Ltd. Jointly Receive Breakthrough Therapy Designation on KN026 by CDE Nov 08 Alphamab Oncology Announces Results of Two Studies of HER2 Bispecific Antibody KN026 At the European Society of Medical Oncology
First half 2023 earnings released: CN¥0.042 loss per share (vs CN¥0.16 loss in 1H 2022) Sep 30
First half 2023 earnings released: CN¥0.042 loss per share (vs CN¥0.16 loss in 1H 2022) Aug 25
Alphamab Oncology Announces Research Updates on KN046 and KN026 for Presentation At ESMO Congress 2023 Aug 11
Alphamab Oncology to Report First Half, 2023 Results on Aug 23, 2023 Aug 09
Alphamab Oncology Announces First Patient Successfully Dosed in Randomized, Controlled, Open-Label, Multi-Center, Phase III Clinical Trial of Kn026 in China Jul 29
Alphamab Oncology Resignation of Xu Zhan Kevin as Non-Executive Director and Member of the Strategy Committee Jul 01
Alphamab Oncology Updates Clinical Research Data for Kn026 in Combination with Kn046 in Her2-Positive Solid Tumors At the Asco 2023 Annual Meeting Jun 06
Alphamab Oncology Updates in Relation to A Phase Iii Clinical Trial of Kn046 for the Treatment of Advanced SQ NSCLC May 20
No longer forecast to breakeven Apr 03 Alphamab Oncology has completed a Follow-on Equity Offering in the amount of HKD 380.5 million. Feb 11
Forecast to breakeven in 2025 Dec 31
Alphamab Oncology Presents Clinical Data of Kn026 Combined with Docetaxel as Neoadjuvant Treatment for Her2-Positive Early or Locally Advanced Breast Cancer At Sabcs 2022 Dec 13
Alphamab Oncology Presented Final Analysis of KN046 Combined with Nab-paclitaxel in the Treatment of mTNBC at SABCS 2022 Dec 12
Alphamab Oncology Announces Results from Three Clinical Studies of KN026 and KN046 Nov 22
Alphamab Oncology Receives IND Approval by NMPA for A Phase Ia/Ib Clinical Trial of JSKN003 for the Treatment of Advanced Solid Tumors Oct 28
Alphamab Oncology Announces First Patient Dosed in A Phase I Clinical Trial of JSKN003 (KN026-ADC) in Australia for the Treatment of Advanced Solid Tumors Sep 20
Alphamab Oncology Presents the updated data from Phase 2 Clinical trial on KN046 Combined with platinum doublet chemotherapy as first-line(1L)treatment for NSCLC at ESMO 2022 Sep 14
Alphamab Oncology Announces Updates on Clinical Data of KN046 and KN026 Sep 07
Alphamab Oncology Announces Updates on Clinical Data of KN046 and KN026 Sep 06
Alphamab Oncology to Report First Half, 2022 Results on Aug 31, 2022 Aug 19
Alphamab Oncology Announces First Patient Dosed in Phase II Clinical Trial of KN046 Combined with Axitinib for the First-Line Treatment of Advanced NSCLC Aug 09
Alphamab Oncology Announces Board and Committee Changes Jun 17
Alphamab Oncology Announces First Patient Dosed in Phase I Trial of PD-L1/OX40 Bispecific Antibody KN052 Jun 14
Alphamab Oncology Announces First Patient Dosed in A Phase Ii Clinical Trial of Kn026 Combined with Palbociclib and Fulvestrant for the Treatment of Locally Advanced Unresectable or Metastatic Her2-Positive Breast Cancer May 27
No longer forecast to breakeven Apr 27
Less than half of directors are independent Apr 27
Alphamab Oncology Updates on Clinical Data of Kn046 in Combination with Kn026 for the Treatment of Her2-Positive Solid Cancer for Presentation at 2022 AACR Annual Meeting Apr 12
No longer forecast to breakeven Apr 07
Alphamab Oncology Announces Completion of Phase III Clinical Trial of KN046 Apr 01
Alphamab Oncology, Annual General Meeting, Jun 10, 2022 Mar 31
Alphamab Oncology, Annual General Meeting, Jun 10, 2022 Mar 30 Alphamab Oncology to Present Clinical Data of KN026 Combined with KN046 in HER2-positive Solid Tumors at AACR 2022 Mar 10
Alphamab Oncology Announces Publication of Clinical Results of Kn026 in Her2-Positive Breast Cancer in Clinical Cancer Research Feb 24 Alphamab Oncology Announces IND Approval of PD-L1/OX40 Bispecific Antibody KN052
Alphamab Oncology Announces First Patient Dosed in A Phase III Clinical Trial of KN046 for the Treatment of Advanced PDAC Feb 10
Alphamab Oncology announces Enrollment Completed in Phase II Clinical Study of KN026 Combined with KN046 Jan 13
Alphamab Oncology and CSPC Pharmaceutical Group Co., Ltd. Announce Approval of IND Application for Pivotal Clinical Study of HER2 Bispecific Antibody KN026 Combined with Chemotherapy in Gastric Cancer Jan 06
Forecast to breakeven in 2024 Jan 01
Alphamab Oncology Announces First Patient Dosed in the U.S. in a Phase II Pivotal Clinical Study of Kn046 Dec 23
Alphamab Oncology Announces IND Application for Phase 3 Registration Study of Kn046 in Combination with Chemotherapy for the Treatment of Pancreatic Cancer Nov 26
Alphamab Oncology Announces IND Approval by NMPA for a Phase III Clinical Trial of KN046 for the Treatment of Advanced PDAC Nov 24
Independent Non-Executive Director Hualiang Jiang has left the company Aug 28
Alphamab Oncology Presents Phase 2 Clinical Data on Kn046 Jun 08
Alphamab Oncology Presents Multiple Clinical Research Data At the 2021 American Society of Clinical Oncology Annual Meeting May 21
Alphamab Oncology to Report Fiscal Year 2020 Results on Mar 23, 2021 Mar 12
Alphamab Oncology Announces Approval for Phase II Clinical Trial of KN046 in the U.S Mar 09
Alphamab Oncology and 3D Medicines Announces Envafolimab Granted Priority Review by NMPA Jan 20
Alphamab Oncology Announces Abstracts on Clinical Data from Phase II Clinical Study of KN046 in Patients with Advanced NSCLC and Preliminary Results of KN046 in Patients with Rare Thoracic Tumors for Presentation at WCLC 2020 Jan 14 Rendimenti per gli azionisti 9966 HK Biotechs HK Mercato 7D -8.1% -4.3% -3.0% 1Y -46.3% -12.6% 15.1%
Vedi i rendimenti completi degli azionisti
Ritorno vs Industria: 9966 ha avuto una performance inferiore rispetto al Hong Kong Biotechs che ha registrato un rendimento -12.6 % nell'ultimo anno.
Rendimento vs Mercato: 9966 ha avuto una performance inferiore al mercato Hong Kong che ha registrato un rendimento 15.1 % nell'ultimo anno.
Volatilità dei prezzi Is 9966's price volatile compared to industry and market? 9966 volatility 9966 Average Weekly Movement 8.3% Biotechs Industry Average Movement 8.3% Market Average Movement 6.7% 10% most volatile stocks in HK Market 14.3% 10% least volatile stocks in HK Market 3.1%
Prezzo delle azioni stabile: 9966 non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi rispetto al mercato Hong Kong.
Volatilità nel tempo: La volatilità settimanale di 9966 è diminuita da 14% a 8% nell'ultimo anno.
Informazioni sull'azienda Alphamab Oncology, azienda biofarmaceutica in fase clinica, si occupa di ricerca e sviluppo, produzione e commercializzazione di farmaci biologici oncologici. La sua pipeline di prodotti comprende KN046, un anticorpo monoclonale bispecifico (BsAb) inibitore del checkpoint immunitario, che ha come bersaglio i checkpoint immunitari clinicamente validati, tra cui il ligando della morte programmata 1 (PD-L1) e la proteina 4 associata ai linfociti T citotossici (CTLA-4); e KN026, un BsAb di nuova generazione contro il recettore 2 del fattore di crescita epidermico umano (HER2), in fase III di sperimentazione clinica per il trattamento del carcinoma mammario HER2-positivo e in fase I e II di sperimentazione clinica per il trattamento di tumori HER2 pesantemente pretrattati, nonché in fase II di sperimentazione clinica per il trattamento di tumori solidi HER2-positivi non selezionabili o metastatici. La pipeline di prodotti dell'azienda comprende anche KN035, un inibitore iniettabile di PD-L1 che è in fase III di sperimentazione clinica per il trattamento neoadiuvante/adiuvante del carcinoma polmonare non a piccole cellule e del carcinoma endometriale; e KN019, una proteina di fusione immunosoppressiva basata su CTLA-4, per le malattie autoimmuni e i disordini immunitari indotti dal trattamento oncologico.
Mostra di più Alphamab Oncology Riepilogo dei fondamenti Come si confrontano gli utili e i ricavi di Alphamab Oncology con la sua capitalizzazione di mercato? 9966 statistiche fondamentali Capitalizzazione di mercato HK$3.15b Guadagni(TTM ) -HK$228.97m Ricavi(TTM ) HK$271.70m
Guadagni e ricavi Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM) 9966 Conto economico (TTM ) Ricavi CN¥255.87m Costo del fatturato CN¥52.88m Profitto lordo CN¥202.99m Altre spese CN¥418.62m Guadagni -CN¥215.63m
Ultimi guadagni dichiarati
Jun 30, 2024
Prossima data di guadagno
n/a
Utile per azione (EPS) -0.22 Margine lordo 79.33% Margine di profitto netto -84.27% Rapporto debito/patrimonio netto 19.6%
Come si è comportato 9966 nel lungo periodo?
Vedi performance storica e confronto
Analisi aziendale e situazione dei dati finanziari Dati Ultimo aggiornamento (ora UTC) Analisi dell'azienda 2025/01/10 06:36 Prezzo dell'azione a fine giornata 2025/01/10 00:00 Guadagni 2024/06/30 Guadagni annuali 2023/12/31
Fonti dei dati I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC . I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
Pacchetto Dati Tempistica Esempio Fonte USA * Dati finanziari della società 10 anni Conto economico Rendiconto finanziario Bilancio Stime di consenso degli analisti +3 anni Previsioni finanziarie Obiettivi di prezzo degli analisti Prezzi di mercato 30 anni Prezzi delle azioni Dividendi, scissioni e azioni Proprietà 10 anni Top azionisti Insider trading Gestione 10 anni Team di leadership Consiglio di amministrazione Sviluppi principali 10 anni
* esempio per i titoli statunitensi, per quelli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più , cliccate qui .
Modello di analisi e Snowflake I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github ; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube .
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su .
Fonti analitiche Alphamab Oncology è coperta da 8 analisti. 3 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
Analista Istituzione Wangbin Zhou Citigroup Inc null null CLSA null null Guoyuan Securities (HK) Ltd
Mostra 5 altri analisti 